Discovery and development of triptans
Triptans is a word commonly used for a class of anti-migraine drugs that are selective 5-hydroxytryptamine/serotonin1B/1D (5-HT1B/1D) agonists. Migraine is a complex disease which affects about 15% of the population and can be highly disabling. Triptans have advantages over ergotamine and dihydroergotamine, such as selective pharmacology, well established safety record and evidence-based prescribing instructions. Triptans are therefore often preferred treatment in migraine.
Search for a new anti-migraine drug started at Glaxo in 1972. Studies in the 1960s showed that vasoconstriction from 5-HT, ergotamine and noradrenaline could reduce migraine attacks. Research also showed that platelet 5-HT level is reduced during migraine. Because there are too many side-effects for 5-HT to be used as a drug, scientists started research on the receptors of 5-HT in order to discover and develop a more specific agonist for 5-HT receptors. Research on the 5-HT receptors and their effect led to discovery of several types and subtypes of 5-HT. AH24167 showed a vasodilation effect instead of vasoconstriction due to the agonist effect on another type of 5-HT receptors later assigned the name 5-HT7. AH25086 was the second compound developed and showed a vasoconstriction effect but was not released as a drug due to low per oral bioavailability. Continued research led to the discovery of the first triptan drug, sumatriptan, that had both vasoconstriction effect, as well as better oral bioavailability. Sumatriptan was first launched in the Netherlands in 1991 and became available in the USA during 1993.
Triptans are specific and selective agonists for the 5-HT1 receptors. Sumatriptan binds to 5-HT1D receptors, zolmitriptan, rizatriptan, naratriptan, almotriptan, and frovatriptan binds to 5-HT1B/1D and eletriptan binds to 5-HT1B/1D/1F receptors. Triptans supposed mechanism of action are vasoconstriction effect on carotid arterial circulation without affecting cerebral blood flow, peripheral neuronal inhibition and inhibition of transmission through second order neurons of the trigeminocervical complex. 
5-HT receptors are all G-protein coupled receptors (GPCR) except for 5-HT3 which is a ligand gated ion channel. The receptors that have been found to be involved in migraine are 5-HT1B, 5-HT1D and 5-HT1F receptors. 5-HT1B are found in meningeal arteries, agonism of 5-HT1B causes vasoconstriction in cranial nerves. The 5-HT1D receptors are located primarily in the trigeminal nerve in the central nervous system (CNS). They are also found in vascular smooth muscles, mediating contraction. Agonism of 5-HT1D receptors subdues the release of inflammatory inducing nerve stimulants. The amino acids contributing to the binding of ligands to the receptor are aspartic acid (Asp), phenylalanine (Phe), serine (Ser), threonine (Thr), tryptophan (Trp) and tyrosine (Tyr). It has been shown that both 5-HT1B and 5-HT1D receptors in humans have a very similar amino acids structures which demonstrates the similarities in binding properties.
All triptans have an indole structure identical to the neurotransmitter 5-HT. Classic triptan structure contain side chain on the indole ring, and a basic nitrogen in a similar distance from the indole structure. The main structural difference of the triptans is the position of the sulfonamide and the side chain attached to it (see figure 1 and table 1). Rizatriptan and zolmitriptan have instead of a sulfonamide a triazole and 2-oxazolidone respectively. Another exception to the classic structure is seen on eletriptan where the nitrogen-alkyl chain connected to the indole ring is replaced with a dimethyl-pyrrolidine, and in naratriptan where the nitrogen-alkyl chain is replaced with an 1-methyl-piperidine ring.
Structures of the triptan analogues
Important structural features of triptans and binding to the receptor
The following chemical attributes on 5-HT1B/1D agonists have been found to contribute to the binding/efficacy on the 5-HT1B and 5-HT1D receptors:
- An aromate
- Protonated nitrogen (ion bonds)
- Atoms that can form hydrogen bonds (hydrogen bond receptor)
There are important structural features that are decisive in binding to the receptor. Triptan structures were designed from the structure of 5-HT to attain affinity to 5-HT receptors, hence the identical indole structure. The hydroxyl group (-OH) on the hexane of the indole core and the alkyl-amine side chain on position C3 on 5-HT have been replaced with other compounds, such as sulfonamides or azol-ring structured derivatives and different amine-alkyl side chains. An electro-negative group can form a hydrogen bond with Thr in the pocket of the receptor. Sulfonamide derivatives attached to the hexane ring of the indole structure have electro-negative properties, as well as the triazole and 2-oxazolidone on rizatriptan and zolmitriptan respectively. This can increase binding ability of the compound and the efficacy, especially with the 5-HT1D receptor.
A schematic drawing of the binding of sumatriptan to 5-HT1D receptor can be seen in figure 2. One study showed that sumatriptan fits better in the binding site of the receptor when the side chain with the protonated nitrogen atom is folded back over the indole structure. This alignment contributes to the hydrogen bonding between the nitrogen in the sulfonamine and the Ser138 in the binding site. It is also favorable to the formation of the hydrogen bond between the oxygen of the sulfonamine and Thr202. Other binding in the pocket of the binding site occurs with the nitrogen atom in the pentene ring of the indole structure of the triptan and the amino acid Ser352. This energetically favorable position of the agonist makes it possible for additional binding of the ligand to other Ser in the binding site, along with additional anchoring between Phe in the pocket of the binding site and the indole of the agonist. The binding of Phe and the triptan is caused by π stacking interactions of the indole and amino acid and an additional effect on this interaction is because of dispersive effect of amino acid leucine (Leu)(not shown in figure 2). The amino acids Trp343 and Tyr346 both have electron rich π-systems in their aromatic structures. With their position in the binding site they create a sort of aromatic cage around the protonated nitrogen atom of the side chain on position C3 on the triptans (this nitrogen atom is protonated at physiological condition), and thereby stabilizes the ion bond the nitrogen atom has formed with a carboxylate on aspartic acid. Side chains of the surrounding amino acids can have an effect on the binding of the nitrogen atom, mainly three Phe can affect the methyl groups bound to the nitrogen atom (not shown in figure 2).
By placing an electron-withdrawing group or large group on position C2 on the indole structure the 5-HT agonist is conversed into an antagonist. This is thought to be because the indole ring is unable to occupy the aromatic part of the binding site.
Properties of formulations
Sumatriptan was the pioneer drug in this class. The second generation's triptans such as zolmitriptan, naratriptan, rizatriptan, almotriptan, eletriptan and frovatriptan soon became available. Different triptans are available in different formulations and in different strengths (see table 2). They have been formulated as subcutaneous injections, oral tablets, orally disintegrating tablets, nasal spray and as rectal suppositories. Delivery system of the triptans may play an important role in the onset of action. The selection of anti-migraine drug for patients depends on their symptoms. The first selective 5-HT1B/1D agonist, sumatriptan, was first synthesized as a subcutaneous injection, then as an oral tablets and more recently as a nasal spray, it is also available in some countries as suppositories. The subcutaneous injection is the fastest way to stop a rapidly progressing migraine attacks. The sumatriptan nasal spray provides faster onset of action than the tablets but it produces a similar headache response at 2 hours. Some patients prefer the nasal spray as it works more rapidly than the tablets and does not have as many adverse effects as the subcutaneous injection. Nasal spray is although not suitable for all patients, because some patients experience bad taste and lack of consistency of response. Zolmitriptan was developed with the strategy to create a more lipophilic compound, with faster absorption and better ability to cross the blood brain barrier than sumatriptan. It is available as tablets, orally disintegrating tablets and as nasal spray in some countries. Rizatriptan is available as tablets and orally disintegrating tablets but naratriptan, almotriptan, eletriptan and frovatriptan are only available in tablets, for now.
daily dose (mg)
of action (min)
25, 50, 100
a Specific enzyme not yet reported.
The U.S. Food and Drug Administration (FDA) approved a new drug April 15, 2008, which is a combination of sumatriptan 85 mg and naproxen 500 mg (NSAID). Triptans and NSAIDs work on distinct mechanism involved in migraine and therefore may offer improved treatment when administrated together.
Patients seek rapid onset of action to relief the headache. Relatively short tmax, good bioavailability and lipophilicity are pharmacokinetic properties that have been associated with rapid onset of action. It has been speculated that good ability to cross the blood brain barrier and relatively long terminal elimination half-life may result in a lower incidence of headache recurrence. Sumatriptan and rizatriptan undergo first pass hepatic metabolism and result in lower bioavailability.
|t1/2 (h)||tmax (h)||ClR
|Naratriptan||63(M) / 74(F)||High||28–31||5–6||2–3||220||-0.2||2.4 L/kg|
|Rizatriptan||47||Moderate||14||2–2.5||1.3||414||-0.7||140(M) / 110(F) L|
|Frovatriptan||24(M) / 30(F)||Low||20–30||2–5||2–4||216(M) / 132(F)||-1.0||4.2(M) / 3.0(F) L/kg|
t1/2 = Elimination half-life; tmax = Time to reach peak plasma drug concentration; ClR = Renal Clearance; LogDpH7.4 = Measure of lipophilicity at pH 7.4. Increasing number indicate greater solubility; VD = Volume of distribution
M = Male; F = Female
Most triptans were developed and introduced in the 1990s. Further studies have not shown much promise regarding the development of new triptans with better duration of action, efficacy and safety profile. Therefore it is unlikely that further variations will be developed and new anti-migraine drugs are likely to have another mechanism of action.
- Ferrari, M. D.; Goadsby, P.J.; Roon, K. I.; Lipton, R.B. (2002), "Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials", Cephalalgia 22 (8): 633–658, doi:10.1046/j.1468-2982.2002.00404.x, PMID 12383060
- Goadsby, Peter J. (2006), "Recent advances in understanding migraine mechanism, molecules and therapeutics" (PDF), Trends in molecular medicine 13 (1): 39–44, doi:10.1016/j.molmed.2006.11.005, PMID 17141570
- Humphrey, Patrick P.A. (2007), "The Discovery of a New Drug Class for the Acute Treatment of Migraine", Headache, 47 [Suppl 1]: 10–19, doi:10.1111/j.1526-4610.2007.00672.x, PMID 17425704
- "Imigran Tablets 50mg Imigran Tablets 100mg". Retrieved 2008-11-09.
- "Zomig Tablets 2.5mg". Retrieved 2008-11-09.
- "Maxalt 5mg, 10mg Tablets, Maxalt Melt 10mg Oral Lypophilisates". Retrieved 2008-11-09.
- "Naramig Tablets 2.5mg". Retrieved 2008-11-09.
- "Axert". Retrieved 2008-11-09.
- "Migard". Retrieved 2008-11-09.
- "Relpax – 20 mg and 40 mg". Retrieved 2008-11-09.
- Bremner, DH; Ringan, NS; Wishart, G (1997), "Modeling of the agonist binding site of serotonin human 5-HT1A, 5-HTDα and 5-HTDβ receptors" (PDF), European Journal of Medicinal Chemistry 32: 59–69
- Bojarski, Andrzej J. (2006), "Pharmacophore Models for Metabotropic 5-HT Receptor Ligands", Current Topics in Medicinal Chemistry 6 (18): 2005–2026, doi:10.2174/156802606778522186, PMID 17017971
- Terzioglu, Nalan; Höltje, Hans-Dieter (2005), "Receptor-based 3D QSAR Analysis of Serotonin 5-HT1D receptor agonists", Collection of Czechoslovak Chemical Communications 70: 1482–1492, doi:10.1135/cccc20051482
- Mathew, Ninan T.; Loder, Elizabeth W. (2005), "Evaluating the triptans", The American Journal of Medicine 118: 28–35, doi:10.1016/j.amjmed.2005.09.014, PMID 16356805
- Bigal, Marcelo E.; Bordini, Carlos A.; Antoniazzi, Ana L.; Speciali, José G (2003), "The triptan formulations, A critical evaluation" (PDF), Arquivos de Neuro-Psiquiatria 61 (2A): 313–320, doi:10.1590/s0004-282x2003000200032, PMID 12806521
- "Drug class review: Oral 5HT1 Receptor agonists" (PDF). U.S. Department of Veterans Affairs. Retrieved 2008-11-03.
- Armsterong, Scott C.; Cozza, Kelly L. (2002), "Triptans", Psychosomatics 43 (6): 502–504, doi:10.1176/appi.psy.43.6.502, PMID 12444236
- Rapoport, Alan M.; Tepper, Stewart J.; Sheftell, Fred D.; Kung, Edna; Bigal, Marcelo E. (2006), "Which triptan for which patient?" (PDF), Neurological Sciences 27: 123–129, doi:10.1007/s10072-006-0586-y
- Färkkilä, M.; Dalhlöf, C.; Stovner, L.J.; Bruggen, J.P ter; Rasmussen, S.; Muirhead, N.; Sikes, C.; Sikes, C (2003), "Eletriptan for the treatment of migrain in patients with previous poor response or toletance to oral sumatriptan", Cephalalgia 23 (6): 463–471, doi:10.1046/j.1468-2982.2003.00554.x, PMID 12807526
- "press release - Treximet (sumatriptan and naproxen sodium) tablets approved by FDA for acute treatment of migraine". GlaxoSmithKline. Retrieved 2008-11-09.
- Smith, Timothy R.; Sunshine, Abraham; Stark, Stuart R.; Littlefield, Diane E.; Spruill, Susan E.; Alexander, W. James (2005), "Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine", Headache 45 (8): 983–991, doi:10.1111/j.1526-4610.2005.05178.x, PMID 16109111
- Jhee, Stanford S.; Shiovitz, Thomas; Crawford, AAron W.; Cutler, Neal R. (2001), "Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents", Clinical Pharmacokinetic 40: 189–205, doi:10.2165/00003088-200140030-00004
- Saxena, Pramod R.; Tfelt-Hansen, Peer (2001), "Success and failure of triptans" (PDF), The Journal of Headache and Pain 2: 3–11, doi:10.1007/s101940170040
- Pascual, Julio; Muñoz, Pedro (2005), "Correlation between lipophilicity and triptan outcomes", Headache 45 (1): 3–6, doi:10.1111/j.1526-4610.2005.05003.x, PMID 15663606
- Lambert, Geoffrey A. (2005), "Preclinical Neuropharmacology of Naratriptan", CNS Drug reviews 11 (3): 289–316, doi:10.1111/j.1527-3458.2005.tb00048.x, PMID 16389295